The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
45 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $52,297,732 in first-year total cost, median $775,183.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BBBP-Z (55)]26
- Special Emphasis Panel[ZRG1 BBBP-V (55)]16
- Special Emphasis Panel[ZRG1 BBBP-B (55)]3
Most frequent institutions
- COGNITION THERAPEUTICS, INC.4
- COLUMBIA UNIVERSITY HEALTH SCIENCES3
- INDIANA UNIVERSITY INDIANAPOLIS2
- UNIVERSITY OF MINNESOTA2
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease1R01AG058660-01 | CATALANO, SUSAN M | COGNITION THERAPEUTICS, INC., PA | $5,059,534 | ZRG1 |
| 2018 | The LUCINDA Trial1R01AG057681-01A1 | ATWOOD, CRAIG SBUTLER, TRACY A.GALVIN, JAMES E | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $1,603,736 | ZRG1 |
| 2018 | Novel Cognitive and Functional Measure for Alzheimer's Disease Prevention Trials1R01AG051346-01A1 | GOLDBERG, TERRYHARVEY, PHILIP D.SCHNEIDER, LON S | NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC, NY | $1,595,795 | ZRG1 |
| 2018 | Neuron regenerative therapeutic, NNI-362, for first-in-human safety and PK for AD1R01AG056561-01A1 | KELLEHER-ANDERSSON, JUDITH A | NEURONASCENT, INC., MD | $1,575,691 | ZRG1 |
| 2018 | Effects of Alzheimer's disease clinical trial study partners1RF1AG059407-01 | GILLEN, DANIEL LGRILL, JOSHUA | UNIVERSITY OF CALIFORNIA-IRVINE, CA | $1,276,222 | ZRG1 |
| 2018 | Novel automated performance-based ADL outcomes for early AD clinical trials1R01AG053184-01A1 | MARSHALL, GAD ASHER | BRIGHAM AND WOMEN'S HOSPITAL, MA | $883,247 | ZRG1 |
| 2018 | Treating mild cognitive impairment with transcranial direct current stimulation1R01AG058724-01 | HAMPSTEAD, BENJAMIN MICHAEL | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $870,064 | ZRG1 |
| 2018 | Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders1R01AG058417-01A1 | SLOAN, RICHARD PSMALL, SCOTT A | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $825,082 | ZRG1 |
| 2018 | Enhanced Mediterranean Diet for Alzheimer's Disease Prevention1R01AG060157-01 | BURNS, JEFFREY MURRAYSULLIVAN, DEBRA K | UNIVERSITY OF KANSAS MEDICAL CENTER, KS | $758,906 | ZRG1 |
| 2018 | The effect of physical activity on cognition relative to APOE genotype (PAAD-II)1R01AG058919-01 | ETNIER, JENNIFER L | UNIVERSITY OF NORTH CAROLINA GREENSBORO, NC | $730,680 | ZRG1 |
| 2018 | Optimizing Cognitive Assessment in DIAN with Smartphone-based burst testing1R01AG057840-01A1 | HASSENSTAB, JASON J | WASHINGTON UNIVERSITY, MO | $730,239 | ZRG1 |
| 2018 | Rhythm Experience and Africana Culture Trial (REACT)1R01AG060741-01 | ERICKSON, KIRK I | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $699,436 | ZRG1 |
| 2018 | Assessment of lenalidomide to treat Alzheimer's disease1R01AG059008-01 | DECOURT, BORISSABBAGH, MARWAN NOEL | CLEVELAND CLINIC LERNER COM-CWRU, OH | $496,020 | ZRG1 |
| 2018 | Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment1R01AG059654-01 | LI, DANNI | UNIVERSITY OF MINNESOTA, MN | $490,750 | ZRG1 |
| 2018 | A Randomized Controlled Trial of Visual Cues, Signage, and Spaced-Retrieval Education within Long Term Care Communities to Assist with Wayfinding1R01AG056384-01A1 | DAVIS, REBECCA | GRAND VALLEY STATE UNIVERSITY, MI | $445,552 | ZRG1 |
| 2018 | Biomarker Predictors of Memantine Sensitivity in patients with Alzheimer's Disease1R01AG059640-01 | SWERDLOW, NEAL R | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $392,500 | ZRG1 |
| 2017 | Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease1R01AG053798-01A1 | AISEN, PAUL S.CUMMINGS, JEFFREY L.SPERLING, REISA A. | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $5,001,194 | ZRG1 |
| 2017 | A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Subjects with Mild to Moderate Alzheimer's Disease1RF1AG057553-01 | CATALANO, SUSAN M | COGNITION THERAPEUTICS, INC., PA | $4,130,741 | ZRG1 |
| 2017 | A Pilot CSF Catheter Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Clearance into CSF in Subjects with Mild to Moderate Alzheimerʼs Disease1RF1AG057780-01 | CATALANO, SUSAN M | COGNITION THERAPEUTICS, INC., PA | $2,527,271 | ZRG1 |
| 2017 | Multidomain Alzheimers Risk Reduction Study (MARRS) Pilot1R01AG057508-01 | LARSON, ERIC BYAFFE, KRISTINE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $1,371,136 | ZRG1 |
| 2017 | Anti-Viral therapy in Alzheimer's disease1R01AG055422-01A1 | DEVANAND, DAVANGERE P | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $1,327,757 | ZRG1 |
| 2017 | Phase II RCT of High-dose Vitamin D Supplements in Older Adults without Dementia1R01AG051618-01A1 | OLICHNEY, JOHN M | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $960,877 | ZRG1 |
| 2017 | Modified Ketogenic Diet Effects on Alzheimer's Disease Biomarkers and Cognition in Mild Cognitive Impairment1R01AG055122-01 | CRAFT, SUZANNE | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $954,203 | ZRG1 |
| 2017 | Multicultural Healthy Diet to Reduce Cognitive Decline & Alzheimer Disease Risk1R01AG055527-01A1 | MOSSAVAR-RAHMANI, YASMIN | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC, NY | $856,849 | ZRG1 |
| 2017 | Circadian rhythm disturbance and agitation in Alzheimer's disease1R01AG054771-01 | ROSENBERG, PAUL BWU, MARK N | JOHNS HOPKINS UNIVERSITY, MD | $797,636 | ZRG1 |
| 2017 | COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT1R01AG052440-01A1 | DEVANAND, DAVANGERE P | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $781,608 | ZRG1 |
| 2017 | Efficacy and Mechanisms of Combined Aerobic Exercise and Cognitive Training in MCI (The ACT Trial)1R01AG055469-01A1 | LIN, FENG VANKEEYU, FANG | UNIVERSITY OF MINNESOTA, MN | $776,403 | ZRG1 |
| 2017 | Exercise for Brain Health with Increased Genetic Risk for Alzheimer's Disease1R01AG057552-01 | SMITH, JEROME CARSON | UNIV OF MARYLAND, COLLEGE PARK, MD | $775,183 | ZRG1 |
| 2017 | MIND Food and Speed of Processing Training in Older Adults with Low Education, The MINDSpeed Alzheimer's Disease Prevention Pilot Trial1R01AG052439-01A1 | CLARK, DANIEL OUNVERZAGT, FREDERICK W. | INDIANA UNIVERSITY INDIANAPOLIS, IN | $763,405 | ZRG1 |
| 2017 | Interventions to Attenuate Cognitive Decline1R01AG056428-01A1 | EDWARDS, JERRI | UNIVERSITY OF SOUTH FLORIDA, FL | $739,503 | ZRG1 |
| 2017 | Enriching clinical trials requiring amyloid positivity with practice effects1R01AG055428-01A1 | DUFF, KEVIN MHOFFMAN, JOHN M | UNIVERSITY OF UTAH, UT | $730,318 | ZRG1 |
| 2017 | Evaluation of Brain and Cognitive Changes in Older Adults with MCI Taking Lithium to Prevent Alzheimer Type Dementia1R01AG055389-01 | GILDENGERS, ARIEL GERARD | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $728,145 | ZRG1 |
| 2017 | The delivery of essential fatty acids to the Brain in Alzheimer's disease1R01AG054434-01A1 | YASSINE, HUSSEIN N | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $708,721 | ZRG1 |
| 2017 | Decreasing Alzheimer's Disease and Related Dementias after Delirium-Exercise and Cognitive Training (DDD-ECT)1R01AG055391-01 | KHAN, BABAR A | INDIANA UNIVERSITY INDIANAPOLIS, IN | $702,719 | ZRG1 |
| 2017 | Communication Bridge: A person-centered Internet-based intervention for individuals with primary progressive aphasia1R01AG055425-01A1 | ROGALSKI, EMILY J | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $663,165 | ZRG1 |
| 2017 | In Silico Screening of Medications for Slowing Alzheimer's Disease Progression.1R01AG057684-01 | KENNEDY, RICHARD ESCHNEIDER, LON S | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $658,103 | ZRG1 |
| 2017 | Age- Related Mild Cognitive Impairment and novel protective role of Glutathione: implications for Alzheimer's Disease1R01AG054131-01A1 | SEKHAR, RAJAGOPAL VISWANATH | BAYLOR COLLEGE OF MEDICINE, TX | $548,688 | ZRG1 |
| 2017 | Noninvasive Cortical Stimulation to Improve Memory in Mild Cognitive Impairment1R01AG055526-01 | TAYLOR, JOY L | PALO ALTO VETERANS INSTIT FOR RESEARCH, CA | $514,753 | ZRG1 |
| 2017 | Mindfulness Training for Mitigating Age-Related Cognitive Decline in the Elderly1R01AG054427-01 | PRAKASH, RUCHIKA SHAURYA | OHIO STATE UNIVERSITY, OH | $365,677 | ZRG1 |
| 2016 | Phase 1b first-in-patient safety trial for CT1812, a novel Alzheimer’s synaptic protection therapeutic1RF1AG054176-01 | CATALANO, SUSAN M | COGNITION THERAPEUTICS, INC., PA | $2,410,669 | ZRG1 |
| 2016 | A double-blinded, randomized, controlled phase 2a safety, proof-of-concept and exploratory end point trial of the drug LM11A-31 in patients with mild to moderate Alzheimer's disease.1R01AG051596-01A1 | WINDISCH, MANFRED | PHARMATROPHIX, INC., CA | $1,499,874 | ZRG1 |
| 2016 | Conversational engagement as a means to delay onset AD: Phase II1R01AG051628-01A1 | DODGE, HIROKO HAYAMA | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $780,921 | ZRG1 |
| 2016 | Problem Adaptation Therapy for Mild Cognitive Impairment with Depression1R01AG050514-01A1 | KIOSSES, DIMITRIS NROSENBERG, PAUL B | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $772,824 | ZRG1 |
| 2016 | Hyperbaric oxygen therapy for cognition in diabetic elderly at high dementia risk1R01AG051545-01A1 | SANO, MARYSCHNAIDER BEERI, MICHAL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $663,782 | ZRG1 |
| 2016 | INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer’s Symptomatic Expression: The INCREASE study1R01AG054130-01 | JICHA, GREGORY AMOGA, DANIELA CLAUDIA | UNIVERSITY OF KENTUCKY, KY | $352,153 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.